Acasti Pharma, Inc. - (ACST): Price and Financial Metrics


Acasti Pharma, Inc. - (ACST): $0.42

0.01 (+1.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACST Stock Price Chart Interactive Chart >

Price chart for ACST

ACST Price/Volume Stats

Current price $0.42 52-week high $1.79
Prev. close $0.41 52-week low $0.37
Day low $0.40 Volume 39,000
Day high $0.42 Avg. volume 166,032
50-day MA $0.56 Dividend yield N/A
200-day MA $0.88 Market Cap 18.69M

Acasti Pharma, Inc. - (ACST) Company Bio


Acasti Pharma Inc operates as pharmaceutical company. The Company develops drugs for cardiovascular diseases. Acasti offers omega-3 phospholipids a major component of cell membranes.


ACST Latest News Stream


Event/Time News Detail
Loading, please wait...

ACST Latest Social Stream


Loading social stream, please wait...

View Full ACST Social Stream

Latest ACST News From Around the Web

Below are the latest news stories about ACASTI PHARMA INC that investors may wish to consider to help them evaluate ACST as an investment opportunity.

Acasti Pharma Reports Second Quarter 2023 Operational Results

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational results for the second quarter ended September 30, 2022. Recent Highlights The Company expects to receive guidance from the Food and Drug Administration (FD

Yahoo | November 14, 2022

Acasti Pharma to Present at Q4 Investor Summit

LAVAL, Québec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that Jan D’Alvise, President and CEO of Acasti Pharma will be presenting virtually at the Q4 Investor Summit. The Company will be conducting a webcasted presentation and participating in one-on-one meetings with investors. Event: Q4

Yahoo | November 9, 2022

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

Call to be held on Monday, November 14th at 1:00 PM Eastern TimeLAVAL, Quebec, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call at 1:00 PM Eastern Time on Monday, November 14, 2022, to discuss the Company’s corporate progress and other developments, as well as

Yahoo | November 7, 2022

Acasti Announces Court Dismissal of Stockholder Litigation

LAVAL, Québec, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today that a U.S. court has dismissed the remaining stockholder litigation filed in connection with the Company’s acquisition of Grace Therapeutics, Inc. (“Grace”) via merger in August 2021 (the “Merger”). As previously disclosed, four st

Yahoo | September 30, 2022

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) which was held virtually on Wednesday September 28, 2022. Election of Directors All five (5) nominees listed in the proxy statement dated

Yahoo | September 29, 2022

Read More 'ACST' Stories Here

ACST Price Returns

1-mo -26.34%
3-mo -53.33%
6-mo N/A
1-year -69.57%
3-year -97.38%
5-year -96.93%
YTD -66.67%
2021 -51.54%
2020 -86.73%
2019 195.18%
2018 -11.70%
2017 -24.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8179 seconds.